194 related articles for article (PubMed ID: 31243894)
1. Microwave ablation combined with chemotherapy improved progression free survival of IV stage lung adenocarcinoma patients compared with chemotherapy alone.
Li C; Wang J; Shao JB; Zhu LM; Sun ZG; Zhang N
Thorac Cancer; 2019 Jul; 10(7):1628-1635. PubMed ID: 31243894
[TBL] [Abstract][Full Text] [Related]
2. Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Wei Z; Yang X; Ye X; Feng Q; Xu Y; Zhang L; Sun W; Dong Y; Meng Q; Li T; Wang C; Li G; Zhang K; Li P; Bi J; Xue G; Sun Y; Sheng L; Liu B; Yu G; Ren H; Wang J; Sun L; Chen S; Geng D; Zhang B; Xu X; Zhang L; Sun D; Xu X; Diao C; Huang G; Li W; Han X; Wang J; Meng M; Ni Y; Zheng A; Fan W; Li Y; Li F; Fan H; Zou Z; Li Q; Tian H
Eur Radiol; 2020 May; 30(5):2692-2702. PubMed ID: 32020400
[TBL] [Abstract][Full Text] [Related]
3. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone.
Wei Z; Ye X; Yang X; Huang G; Li W; Wang J; Han X
Med Oncol; 2015 Feb; 32(2):464. PubMed ID: 25572816
[TBL] [Abstract][Full Text] [Related]
4. Advanced non small cell lung cancer: response to microwave ablation and EGFR Status.
Wei Z; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Meng M; Ni Y
Eur Radiol; 2017 Apr; 27(4):1685-1694. PubMed ID: 27436020
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed plus cisplatin versus docetaxel plus cisplatin for stage IV lung adenocarcinoma based on propensity score matching.
Su S; Liu L; Geng Y; OuYang W; Ma Z; Li Q; Zhao C; Li M; Wang Y; Luo D; Yang W; He Z; Lu B
Anticancer Drugs; 2019 Mar; 30(3):295-301. PubMed ID: 30489288
[TBL] [Abstract][Full Text] [Related]
6. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
[TBL] [Abstract][Full Text] [Related]
7. Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review.
Zhou F; Yu X; Liang P; Cheng Z; Han Z; Yu J; Liu F; Tan S; Dai G; Bai L
Int J Hyperthermia; 2016 Aug; 32(5):524-30. PubMed ID: 27055684
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy.
Qin Y; Jiang L; Yu M; Li Y; Zhou X; Wang Y; Gong Y; Peng F; Zhu J; Liu Y; Xu Y; Zhou L; Lu Y; Huang M
Sci Rep; 2020 Sep; 10(1):16150. PubMed ID: 32999345
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of systemic chemotherapy combined with radiofrequency ablation and microwave ablation for lung cancer: a comparative study.
Xu F; Song J; Lu Y; Wang J; Wang J; Xiao H; Li Z
Int J Hyperthermia; 2021; 38(1):900-906. PubMed ID: 34148500
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
12. Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC.
Sun YH; Song PY; Guo Y; Pang M; He WN; Zhang WH; Sheng LJ
Genet Mol Res; 2015 Aug; 14(3):10015-25. PubMed ID: 26345938
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
[TBL] [Abstract][Full Text] [Related]
15. [Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung
Adenocarcinoma].
Li P; Li B; Shi Y; Zhang F; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2019 Mar; 22(3):137-142. PubMed ID: 30909992
[TBL] [Abstract][Full Text] [Related]
16. Thermal Ablation of Colorectal Lung Metastases: Retrospective Comparison Among Laser-Induced Thermotherapy, Radiofrequency Ablation, and Microwave Ablation.
Vogl TJ; Eckert R; Naguib NN; Beeres M; Gruber-Rouh T; Nour-Eldin NA
AJR Am J Roentgenol; 2016 Dec; 207(6):1340-1349. PubMed ID: 27680945
[TBL] [Abstract][Full Text] [Related]
17. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
18. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S
Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396
[TBL] [Abstract][Full Text] [Related]
19. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
[TBL] [Abstract][Full Text] [Related]
20. Percutaneous Image-Guided Microwave Ablation for Treating Postsurgical Intrapulmonary Oligometastases or Oligorecurrence.
Zheng QM; Li YY; Zuo TY; Li CH; Sun ZG
J Coll Physicians Surg Pak; 2024 Feb; 34(2):178-182. PubMed ID: 38342868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
